New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
10:16 EDTBCOR, XOMA, JOE, DKS, TDC, TKMR, DRTX, XPO, HMSYHigh option volume stocks
High option volume stocks: TKMR JOE HMSY TDC XOMA XPO VGK DKS BCOR DRTX
News For TKMR;JOE;HMSY;TDC;XOMA;XPO;DKS;BCOR;DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
17:27 EDTTKMRTekmira files to sell $150M of common stock
November 21, 2014
10:26 EDTDKSOptions with decreasing implied volatility
Subscribe for More Information
November 20, 2014
15:14 EDTTKMRTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
10:35 EDTDKSOptions with decreasing implied volatility
Options with decreasing implied volatility: DKS SPLS WB GMCR VRX HTZ WSM VIPS BBY AMAT
November 19, 2014
10:25 EDTDKSOptions with decreasing implied volatility
Subscribe for More Information
07:40 EDTDKSDick's Sporting price target raised to $56 from $51 at Susquehanna
Subscribe for More Information
06:11 EDTTKMRTekmira to host analyst day
Analyst Day to be held in New York on November 21 at 9 am. Webcast Link
November 18, 2014
12:26 EDTBCORBlucora management to meet with Sidoti
Subscribe for More Information
11:28 EDTDKSGoPro rises after company, shareholders file to sell 10.36M shares
Shares of GoPro (GRPO) are rising in early trade after the company filed to sell 10.36M shares of its stock on behalf of the company and its stockholders. WHAT'S NEW: GoPro announced in a prospectus that it is selling about 1.29M shares of class A common stock and that selling stockholders are selling 9.073M shares of class A common stock. The holders of the company's outstanding class B common stock will hold approximately 96.1% of the voting power following this offering, with its executive officers and directors and their affiliates holding approximately 65% and CEO Nicholas Woodman holding approximately 42.5% after his sale of about 4.08M shares of class A common stock in this offering, the company explained. GoPro estimated that it will receive net proceeds of $97.1M from the sale of class A shares, assuming a public offering price of $79.15 per share. The company said it expects to use the net proceeds of this offering for general corporate purposes including working capital, adding that it may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies or assets. "However, we have no present commitments or agreements to enter into any acquisitions or make any investments," GoPro noted. WHAT'S NOTABLE: On November 10, GoPro shares slipped after its CEO acknowledged he planned to sell some of his stake as part of this stock offering. In a regulatory filing at that time, the company shared an email message sent by Woodman to employees, in which he assured that he plans to be a "significant shareholder in GoPro for a long time." Additionally, on its earnings conference call this morning, Dick's Sporting Goods (DKS) management said it continues to be "extremely enthusiastic" about the electronics category, particularly wearables, GoPro cameras, and the Fitbit activity tracker. ANALYST OPINION: In a note to investors this morning, Pacific Crest said channel checks for high end GoPros are looking better than expected. The firm said it sees upside to the upcoming quarter for Ambarella (AMBA), which provides components used by GoPro in its cameras. Pacific Crest increased its price target on Ambarella shares to $55 from $47 and maintains its Outperform rating on the stock. PRICE ACTION: In morning trading, shares of GoPro rose 4.2% to $84.92, while Ambarella (AMBA) gained 5.8% to $51.60.
10:50 EDTDKSDick's Sporting says committed to returning cash to shareholders
Sees FY gross margin declining. Says not exiting golf, Golf Galaxy business.
10:17 EDTDKSDick's Sporting sees retail environment competitive, promotional
Subscribe for More Information
07:34 EDTDKSDick's Sporting sees FY14 EPS ex-items $2.75-$2.85, consensus $2.79
Subscribe for More Information
07:33 EDTDKSDick's Sporting sees Q4 EPS $1.18-$1.28, consensus $1.21
Sees Q4 consolidated same store sales to increase approximately 1%-3%. Q4 revenue consensus $2.12B.
07:32 EDTDKSDick's Sporting reports Q3 EPS 41c, consensus 41c
Reports Q3 revenue $1.53B, consensus $1.53B. Consolidated same store sales increased 1.1%, compared to the company's guidance of an approximate 1%-3% increase. Same store sales for DICK'S Sporting Goods increased 1.7%, while Golf Galaxy decreased 8.9%.
November 17, 2014
15:27 EDTDKSDick's Sporting November 47 straddle priced for 7.1% move into Q3
Subscribe for More Information
15:16 EDTDKSNotable companies reporting before tomorrow's open
Subscribe for More Information
14:58 EDTDKSDick's Sporting technical comments before earnings
Subscribe for More Information
08:44 EDTTKMRNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
08:12 EDTTKMRDicerna announces license agreement with Tekmira for PH1 program
Dicerna Pharmaceuticals (DRNA) announced a licensing agreement for Dicerna to use Tekmira’s (TKMR) proprietary lipid nanoparticle technology for delivery of DCR-PH1, Dicerna’s investigational product candidate for primary hyperoxaluria type 1, a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies. This announcement follows the successful testing of DCR-PH1 in combination with Tekmira's LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront, as well as $22 million in potential development milestones, and a mid-single-digit royalty on future PH1 sales. Tekmira’s LNP system has shown in other human clinical studies to provide potent, safe and effective RNA delivery to hepatocytes. Licensing Tekmira’s LNP will streamline the development path for DCR-PH1 and allows Dicerna to focus its LNP efforts on its oncology pipeline.
08:02 EDTDRTXActavis completes Durata Therapeutics tender offer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use